
Release date: 2024-08-08 16:59:04 Article From: Lucius Laos Recommended: 275
Exkivity improves patient outcomes by inhibiting specific mutant kinases and blocking the proliferation and migration of tumor cells. Exkivity has been approved by the United States FDA and has demonstrated high therapeutic efficacy and a favorable safety profile.
As a targeted therapy, Exkivity has demonstrated a unique therapeutic effect in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. It may also cause a series of adverse reactions, and heart failure is a particularly serious adverse reaction that requires high concern.
Heart failure, referred to as heart failure, is a group of syndromes with clinical manifestations of pulmonary and (or) systemic congestion, insufficient blood perfusion of organs and tissues due to structural or functional diseases of the heart, impaired ventricular filling and/or ejection function, cardiac output can not meet the metabolic needs of the body's tissues, congestion of the pulmonary circulation and/or systemic circulation, and insufficient blood perfusion of organs and tissues, which are mainly manifested as dyspnea, limited physical activity and fluid retention. When Exkivity causes heart failure, the patient's heart's pumping function will be severely affected, resulting in insufficient blood supply to all parts of the body, resulting in systemic symptoms, which may even be life-threatening in severe cases.
In order to effectively prevent and respond to heart failure caused by Exkivity, doctors need to take a series of close monitoring measures before and during treatment.
Symptoms such as a marked decrease in LVEF values, dyspnea, fatigue, and edema are often early signs of heart failure and should be thoroughly evaluated and treated immediately once identified. Treatment may include adjusting the dose of Exkivity or temporarily stopping it, using diuretics and cardiotonics, etc., to reduce the burden on the heart and improve heart function. In severe cases, patients may need to receive a higher level of treatment, such as cardiac resynchronization therapy or a heart transplant.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: